=> file caplus => s 11 L2 93

L2 93 L1 => s 12 and thu/rl

```
=> s e3
         1 WE43/CN
L1
=> d
L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 145684-42-0 REGISTRY
ED Entered STN: 04 Feb 1993
CN Magnesium alloy, base, Mq, Dy, Er, Gd, Li, Nd, Sm, Y, Yb, Zr (WE43) (CA INDEX
    NAME)
OTHER NAMES:
CN Elektron WE43
CN Mg4Y3RE
CN WE43
MF Dy . Er . Gd . Li . Mg . Nd . Sm . Y . Yb . Zr
CI AYS
SR
    CA
LC
    STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
Component Component Component
Percent Registry Number
_____
   Mg 92
            4 2.2
                         7440-65-5
   Nd
                         7440-00-8
   Zr
             0.6
                         7440-67-7
             0.3
                         7429-91-6
   Dy
             0.2
   Gd
                         7440-54-2
   Er
                         7440-52-0
             0.1
   Li
             0.1
                         7439-93-2
             0.1
   Sm
                         7440-19-9
   Yb
             0.1
                         7440-64-4
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
            91 REFERENCES IN FILE CA (1907 TO DATE)
            93 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
977846 THU/RL

=> d ibib abs hit 1-6

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NOMBER: 2007:1473457 CAPLUS <<LOGINID::20080212>>
DOCUMENT NUMBER: 148:85907

TITLE: Implants, especially stents with cholesterol or cholesterol-ester-containing coating
NOVENTOR(S): Korzuschnik, Ellen; Borck, Alexander
PATENT ASSIGNEE (S): Biotronik Vi Patent A.-G., Switz.
```

SOURCE: Ger. Offen., 6pp. CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

> KIND DATE APPLICATION NO. DATE PATENT NO. DE 102006029247 A1 20071227 DE 2006-102006029247 20060626 EP 1872809 A1 20080102 EP 2007-10844 20070601 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU US 2007299512 A1 20071227 US 2007-767878 20070625

DE 2006-102006029247A 20060626 PRIORITY APPLN. INFO.:

AB The invention concerns implants, especially stents with coatings that contain cholesterol or a cholesterol ester, preferably cholesterol linolate. Biocorrodable stents prepared from magnesium alloys are coated. Linoleic acid and drugs can be added to the coating material. Thus a WE43

magnesium allov stent was dip-coated with a solution containing 0.2

cholesterol.

0.2 g α -tocopherol in 3 mL cyclohexane. The dryed stent was implanted into a pig; after 35 days lower restenosis was observed that with

the uncoated control stent. REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Magnesium alloy, base

RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(implants, especially stents with cholesterol or

cholesterol-ester-containing

coating) 145684-42-0, WE43

RL: TEM (Technical or engineered material use); THU (Therapeutic

use); BIOL (Biological study); USES (Uses) (implants, especially stents with cholesterol or

cholesterol-ester-containing

coating)

57-88-5, Cholesterol, biological studies 60-33-3, Linoleic acid, biological studies 604-33-1 137071-32-0, Pimecrolimus

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (implants, especially stents with cholesterol or

cholesterol-ester-containing

coating)

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:800938 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 147:243456

TITLE: Absorbable magnesium alloy drug-eluting stent with multilayer controlled-release coatings, and its

preparation method
INVENTOR(S): Xu, Xinhua; Zhang, Chunhuai; Lu, Ping
PATENT ASSIGNEE(S): Tianjin University, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 8pp.

CODEN: CNXXEV DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

to

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	CN 100998897	A	20070718	CN 2006-10130594	20061227
0	RITY APPLN. INFO.:			CN 2006-10130594	20061227

PRIORITY APPLN. INFO.:

AB The title drug-eluting stent comprises WE43 Mg alloy stent body and multilayer controlled-release coatings. The WE43 Mg alloy contains 3.7-4.3% of Yt, 2.0-2.5% of Nd, 0.4% of Zr, and 0.1-2.4% of Yb, Er and Gd. The multilayer coatings comprises, from the interior to the exterior, a compact anticorrosive coating containing magnesium aluminum oxide or cerium oxide, a cross-linked compact drug-carrying coating containing chitosan or collagen, a non-crosslinked compact drug-carrying coating containing poly(L-lactic acid) or poly(hydroxyacetic acid), and a controlled-release coating containing poly(L-lactic acid) or poly(hydroxyacetic acid). The preparation method comprises processing WE43 Mg alloy to stent body by laser-engraving, subjecting to ultrasound treatment, vacuum-annealing, immersing in an anticorrosive liquid containing Ce(NO3) 3 or Ce(CO3)2 and H202

form an anticorrosive coating, and forming the rest coatings in order by immersion and vacuum-drying. The inventive stent has the advantages of controlled release, good stability and no risk of stripping off.

IT Alloys, biological studies

RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); THU (Therapeutic use); BHOL (Biological study); PROC (Process); USES (Uses)

(absorbable magnesium alloy drug-eluting stent with multilayer controlled-release coatings, and its preparation method)

IT Collagens, biological studies

RL: TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (absorbable magnesium alloy drug-eluting stent with multilayer

controlled-release coatings, and its preparation method)

IT 7429-91-6, Dysprosium, biological studies 7440-00-8, Neodymium, biological studies 7440-64-4, Ytterbium, biological studies 7440-65-5, Yttrium, biological studies 7440-67-7, Zirconium, biological studies 9012-76-4, Chitosan 26009-03-0, Poly(glycolic acid) 26124-68-5, Poly(glycolic acid) 26161-42-2 26811-96-1, Poly(L-lactic acid) 39404-95-0 145684-42-0

RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(absorbable magnesium alloy drug-eluting stent with multilayer controlled-release coatings, and its preparation method)

IT 24512-63-8, Geniposide 53123-88-9, Rapamycin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(absorbable magnesium alloy drug-eluting stent with multilayer
controlled-release coatings, and its preparation method)

IT 7429-90-5, Aluminum, biological studies 7439-95-4, Magnesium, biological studies 7440-45-1, Cerium, biological studies

RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(oxide derivative; absorbable magnesium alloy drug-eluting stent with multilayer controlled-release coatings, and its preparation method)

L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN ACCESSION NUMBER: 2007:67783 CAPLUS <<LOGINID::20080212>> DOCUMENT NUMBER: 146:448100

TITLE: Mechanical properties of degradable magnesium implants

in dependence of the implantation duration

AUTHOR(S): Krause, Chr.; Bormann, D.; Hassel, Th.; Bach, Fr.-W.; Windhagen, H.; Krause, A.; Hackenbroich, Chr.;

Meyer-Lindenberg, A.

Institute of Materials Science, University of Hanover,

Garbsen, 30823, Germany

SOURCE: Magnesium Technology in the Global Age, Proceedings of the International Symposium on Magnesium Technology in

the Global Age, Montreal, QC, Canada, Oct. 1-4, 2006 (2006), 329-343. Editor(s): Pekguleryuz, Mihriban O.; Mackenzie, Luke W. F. Canadian Institute of Mining, Metallurgy and Petroleum: Montreal, Que.

CODEN: 69IUWN; ISBN: 1-894475-66-6

DOCUMENT TYPE: Conference LANGUAGE:

English

Within the scope the collaborative research center 599 (Medical University of Hanover, University of Veterinary Medicine Hanover, University of Hanover) the behavior of the degradation of magnesium materials as implants are investigated by using animal expts. (rabbits). Thus extruded cylindrical pins from the magnesium alloys MgCa0.8%, WE43 and LAE 442 were implanted intramedullary in the tibia diaphyses. The implantation duration was 3 and 6 mo. After the explantation 3 point bending tests were carried out to investigate the possible changes of the mech. properties. Clearly changes in dependence of the implantation duration could be determined. The three magnesium alloys show a decrease of the mech. resistance with an increasing implantation time. To evaluate the degradation process, which is the reason for the changes, micrographs and element analyses (EDX) have been accomplished after the 3 point bending tests. The micrographs show for all used magnesium alloys corroded surfaces but no preferred corrosion on the grain boundarys. The element analyses show beside a layer which is rich in calcium and phosphorus an agglomeration of rare earth elements in this layer. With these results a using of

magnesium alloys as a material for implants can be announced. REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

552290-42-3, LAE 442 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(LAE 442 exhibited decrease in mech. resistance with increasing implantation duration in rabbit)

ΙT 272447-76-4

> RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(MqCa0.8% exhibited decrease in mech. resistance with increasing implantation duration in rabbit)

145684-42-0, WE43 ΙT

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(WE43 exhibited decrease in mech. resistance with increasing implantation duration in rabbit)

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:823616 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 143:199948 TITLE:

Implant for releasing an active substance into a vessel through which a body medium flows and use to implant drugs into blood vessels for the treatment of tumors

INVENTOR(S): Heublein, Bernd; Flach, Erhard; Geistert, Wolfgang; Kolberg, Gernot; Harder, Claus; Rohde, Roland;

Mueller, Heinz

PATENT ASSIGNEE(S): Restate Patent A.-G., Switz.; Heublein, Eva; Heublein,

Nora; Heublein, Christoph SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT	NO.			KIN	D	DATE	ATE APPLICATION NO.							DATE				
WO 2005	A1 20050818				WO 2	005-	20050204											
W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,		
	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,		
	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,		
	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	ΜZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,		
	AZ,	BY,	KG,	KZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,		
	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LT,	LU,	MC,	NL,	PL,	PT,		
	RO,	SE,	SI,	SK,	TR,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,		

MR, NE, SN, TD, TG

DE 102004029611 A1 20050825 DE 2004-102004029611 20040609

CA 2552405 A1 20050818 CA 2005-2552405 20050204

EP 1711213 A1 20061018 EP 2005-701357 20050204

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, ST, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, LS

CN 1905913 A 20070131 CN 2005-80001686 20050204 JP 2007520292 T 20070726 JP 2006-551814 20050204

PRIORITY APPLN. INFO: DE 2004-102004006745A 20040206
DE 2004-102004029611A 20040609
W0 2005-EP1167 W 20050204

B The aim of the invention is to provide an implant for releasing an active substance into a vessel through which a body medium flows. This aim is achieved by the inventive implant for releasing an active substance into a vessel through which a body medium flows. Said implant comprises a base that consists of a biodegradable material as the carrier of the active substance to be released. The body medium flows around said base on the inside and/or outside thereof. Biodegradable magnesium alloys are used as carriers for antitumor drugs; they are implanted into blood vessels for regional drug delivery (RDD).

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT Rare earth metals, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alloy component; implant for releasing an active substance into a vessel through which a body medium flows and use to implant drugs into blood vessels for treatment of tumors)

T Iron alloy, base

Magnesium alloy, base Tungsten alloy, base

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(implant for releasing an active substance into a vessel through which a body medium flows and use to implant drugs into blood vessels for treatment of tumors)

7429-90-5, Aluminum, biological studies 7439-93-2, Lithium, biological studies 7440-65-5, Yttrium, biological studies 7440-67-7, Zirconium, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alloy component; implant for releasing an active substance into a vessel through which a body medium flows and use to implant drugs into blood vessels for treatment of tumors)

7439-89-6, Iron, biological studies 7439-95-4, Magnesium, biological studies 7440-33-7, Tungsten, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(alloy; implant for releasing an active substance into a vessel through which a body medium flows and use to implant drugs into blood vessels for treatment of tumors)

145684-42-0, WE43

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(implant for releasing an active substance into a vessel through which a body medium flows and use to implant drugs into blood vessels for treatment of tumors)

ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:632022 CAPLUS <<LOGINID::20080212>> DOCUMENT NUMBER: 143:120610

TITLE: Radio-opaque marker for medical implants

INVENTOR(S):

Gerold, Bodo; Harder, Claus; Heublein, Bernd; Mueller, Heinz

PATENT ASSIGNEE(S): Restate Patent A .- G., Switz.

SOURCE: Ger. Offen., 6 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent German LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.				KIND DATE							20031224						
	DE	10361942			A1 200					DE 2003-10361942 WO 2004-EP10081								
	WU																	
		W:																
								DE,										
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KΡ,	KR,	ΚZ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NI,
			NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:						MW,										
			AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE.	BG,	CH,	CY,	CZ,	DE,	DK,
			EE.	ES.	FI.	FR.	GB,	GR,	HU.	IE.	IT.	LU.	MC.	NL.	PL.	PT.	RO,	SE.
								CF,										
				TD,		,	,	,	,	,	,	,	· · · /	-21	,	,	,	,
	EP	1696				A1 20060906				EP 2	004-		20040907					
								ES,										
								TR,							1127	,	1107	/
	TTC	2007														2	0070	126
US 2007191708 A1 200708: RIORITY APPLN. INFO.:					0010							A 20031224						
KIUI	XIII	I APP	LIN.	THEO	. :													
														081		W 2		
							WO 2004-EP10081											

The invention concerns radio-opaque markers for medical implants that AB include (a) 10-90 weight/weight% of a biodegradable base; (b) 10-90 weight/weight% of

one or more radio-opaque elements selected from the group of I, Au, Ta, Y,

Nb, Mo, Ru, Rh, Ba, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Os, Ir and Bi; (c) 10 weight/weight% other components. The markers are in form of alloys; biodegradable bases are prepared from substances containing magnesium, iron or zinc; biodegradable polymers can be bases as well. Thus a stent was prepare from the magnesium alloy WE43 and coated by PVD with Mg/Y including 85% Mg and 15% Y.

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 12 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT Polyesters, biological studies

RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lactic acid-based; radio-opaque marker for medical implants)

ΤТ 7429-91-6, Dysprosium, biological studies 7439-88-5, Iridium, biological 7439-91-0, Lanthanum, biological studies 7439-94-3, Lutetium, biological studies 7439-98-7, Molybdenum, biological studies 7440-00-8, Neodymium, biological studies 7440-03-1, Niobium, biological studies 7440-04-2, Osmium, biological studies 7440-10-0, Praseodymium, biological studies 7440-15-5, Rhenium, biological studies 7440-16-6, Rhodium, biological studies 7440-18-8, Ruthenium, biological studies 7440-19-9, Samarium, biological studies 7440-25-7, Tantalum, biological 7440-27-9, Terbium, biological studies 7440-30-4, Thulium, biological studies 7440-33-7, Tungsten, biological studies Barium, biological studies 7440-45-1, Cerium, biological studies 7440-52-0, Erbium, biological studies 7440-53-1, Europium, biological 7440-54-2, Gadolinium, biological studies 7440-57-5, Gold, biological studies 7440-58-6, Hafnium, biological studies Holmium, biological studies 7440-64-4, Ytterbium, biological studies 7440-65-5, Yttrium, biological studies 7440-69-9, Bismuth, biological studies 7553-56-2, Iodine, biological studies 9004-61-9, Hyaluronic acid 9012-76-4, Chitosan 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2ethanedivl)] 26680-10-4, Polylactide 145684-42-0, WE43 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(radio-opaque marker for medical implants)

ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1130051 CAPLUS <<LOGINID::20080212>>

DOCUMENT NUMBER: 142:435701

TITLE:

In vivo corrosion of four magnesium allows and the

associated bone response AUTHOR(S): Witte, F.; Kaese, V.; Haferkamp, H.; Switzer, E.;

Meyer-Lindenberg, A.; Wirth, C. J.; Windhagen, H. CORPORATE SOURCE: Department of Orthopaedic Surgery, Hannover Medical

School, Hannover, 30625, Germany Biomaterials (2005), 26(17), 3557-3563 SOURCE:

CODEN: BIMADU; ISSN: 0142-9612

PUBLISHER: Elsevier Ltd. DOCUMENT TYPE: Journal LANGUAGE: English

Degrading metal alloys are a new class of implant materials suitable for bone surgery. The aim of this study was to investigate the degradation mechanism at the bone-implant interface of different degrading magnesium alloys in bone and to determine their effect on the surrounding bone. Sample rods of four different magnesium alloys and a degradable polymer as a control were implanted intramedullary into the femora of guinea pigs. After 6 and 18 wk, uncalcified sections were generated for histomorphol. anal. The bone-implant interface was characterized in uncalcified sections by SEM, element mapping and X-ray diffraction. Results showed that metallic implants made of magnesium alloys degrade in vivo depending

on the composition of the alloying elements. While the corrosion layer of all magnesium alloys accumulated with biol. calcium phosphates, the corrosion layer was in direct contact with the surrounding bone. The results further showed high mineral apposition rates and an increased bone mass around the magnesium rods, while no bone was induced in the surrounding soft tissue. From the results of this study, there is a strong rationale that in this research model, high magnesium ion concentration could lead to

bone cell activation.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

II Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(lactide; in vivo corrosion of four magnesium alloys and the associated bone response)

IT Magnesium alloy, base

RL: CPS (Chemical process); DEV (Device component use); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(in vivo corrosion of four magnesium alloys and the associated bone response)

IT 12634-54-7, AZ91 12634-55-8, AZ31 145684-42-0, WE43

552290-42-3, LAE442
RL: CPS (Chemical process); DEV (Device component use); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(in vivo corrosion of four magnesium alloys and the associated bone response)

TT 80531-02-8, D-Lactide-L-lactide copolymer

RL: DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(in vivo corrosion of four magnesium alloys and the associated bone response)